William K Bacic bought $10k of PDT
other at JOHN HANCOCK PREMIUM DIVIDEND FUND. 800 shares at an average of $12.55, traded Jan 14, 2025, filed Jan 15, 2025.
Score components
- +8RoleOther
- 0Trade size$10k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001992593-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 14, 2025 | POpen-market purchase common shares of beneficial interest | +800 | $12.55 | $10k | 800 | Jan 15, 2025 |
Related signals
Other insiders at JOHN HANCOCK PREMIUM DIVIDEND FUND and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | PDTbuy JOHN HANCOCK PREMIUM DIVIDEND FUND | Thomas Rowe Wright director | $11k 929 shares | - | |
| 18Weak | PDTbuy JOHN HANCOCK PREMIUM DIVIDEND FUND | Noni Ellison McKee other | $11k 890 shares | +74% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.